产品名称
MISSION® esiRNA, targeting mouse Spry2
description
Powered by Eupheria Biotech
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
CTGCTGCTGCTGATGGAATAATCCGAGTGCAGCCTAAATCGGAGCTCAAGCCTGGTGACGTTAAGCCACTGAGCAAGGATGATTTGGGTCTGCATGCCTACAGGTGTGAGGACTGCGGCAAGTGCAAGTGTAAGGAGTGCACCTACCCGAGGCCCCTGCCGTCGGACTGGATCTGTGACAAGCAGTGCCTCTGCTCAGCCCAGAACGTCATTGACTATGGGACTTGTGTGTGCTGTGTGAAAGGTCTCTTCTATCACTGCTCCAATGACGATGAGGACAATTGTGCTGACAACCCGTGCTCTTGCAGCCAGTCCCATTGTTGTACGCGATGGTCAGCGATGGGAGTCATGTCTCTCTTTTTGCCTTGTTTATGGTGTTACCTTCCAGCCAAGGGTTGCCTTAAATTGTGCCAGGGGTGTT
Ensembl | mouse accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Quality Level
Gene Information
mouse ... SPRY2(24064), Spry2(24064)
General description
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Jun-Ho Ahn et al.
Biomolecules & therapeutics, 23(4), 320-326 (2015-07-15)
The clinical benefits of oncogenic BRAF inhibitor therapies are limited by the emergence of drug resistance. In this study, we investigated the role of a negative regulator of the MAPK pathway, Spry2, in acquired resistance using BRAF inhibitor-resistant derivatives of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持